Strides receives USFDA approval for Fluoxetine Tabs 60 mg

Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules

Strides secures shareholders approval for OneSource CDMO

The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration

Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"

The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression

New Phase II data show vast majority of patients experiencing no relapses or disability progression

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities

Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG

MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)

Mitsubishi Chemical's clinical study demonstrates effectiveness of probiotic on intestinal environment

H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat

Pfizer launches digital platform ‘PfizerForAll’

PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care

Aayush Wellness enters nutraceutical market with Dreamy Sleep Gummies